This comprehensive review elucidates the evolving landscape of PD-L1 as a prognostic biomarker in NMIBC, with a focus on Bacillus Calmette-Guérin (BCG) immunotherapy and on the interaction between PD-L1 and tumor microenvironment in this setting. The gene discussed is CD274; the disease is neoplasm.